カテゴリー： GlobalData, MediPoint, 世界, 医療/バイオ

腫瘍学向けコンパニオン診断の世界市場分析・予測

【英語タイトル】MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

GlobalDataが出版した調査資料（GDME0245MAR）・商品コード：GDME0245MAR
・発行会社（調査会社）：GlobalData
・発行日：2016年12月21日
・ページ数：128
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD5,995 ⇒換算￥653,455見積依頼/購入/質問フォーム
Site License（同一国内共有可）USD11,990 ⇒換算￥1,306,910見積依頼/購入/質問フォーム
Enterprisewide License（複数国内共有可）USD17,985 ⇒換算￥1,960,365見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
【レポートの概要】

MediPoint: Companion Diagnostic Tests in Oncology – Global Analysis and Market Forecasts
Summary

Companion diagnostics is synonymous with personalized, stratified, and precision medicine, and heralds a new era of treatment in which a patients' treatment will become increasingly individualized. A companion diagnostic test is defined as an in vitro diagnostic device or imaging tool whose use allows the safe application of a therapy. In practice, this involves measuring the expression or presence of a specific biomarker that is linked to a disease condition or therapy in order to ascertain how a patient will respond to a particular treatment. A relatively narrow range of core technologies is used for companion diagnostic tests, based around the detection of nucleic acids (such as DNA) or proteins (such as cell surface receptors).

This report focuses on the companion diagnostic testing markets in the US, five major European markets (5EU: France, Germany, Italy, Spain, and the UK), Japan, and the future markets in China, India, and Brazil, to identify unmet needs in the global market, physician attitudes toward current companion diagnostic testing, and the future of companion diagnostic testing in the face of rapid technological advancement. The four major cancers covered in this report are breast cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and melanoma.

Highlights

Key Questions Answered

- What is the current and future companion diagnostics market outlook in the developed and emerging markets? What trends are affecting the global market?
- What is the competitive landscape of major players in the companion diagnostics space across different regions?
- What are the key, high growth markets that manufacturers should expand into? Which market segments are growing the fastest?
- What are the unmet needs with the companion diagnostic tests currently on the market?
- What are the key factors influencing a physician to use companion diagnostic tests? What is physician perception and market outlook of these devices?
- What are the challenges and barriers that have hindered widespread adoption of companion diagnostic testing?

Scope

- Competitive assessment: Currently marketed companion diagnostic products and evolving competitive landscape
- In-depth analysis of unmet needs and adoption trends of different companion diagnostic tests
- Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
- Pipeline analysis: Emerging products and technologies.
- Annualized total companion diagnostic market volume and revenue by segment, and market outlooks by country from 2014-2023.
- Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.

Reasons to buy

The report will enable you to –
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the global market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Track device sales in the global market from 2014-2023
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

【レポートの目次】

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Companion Diagnostics Overview 14
2.2 Catalyst 15
2.3 Related Reports 15
3 Market Opportunities 16
3.1 Market Drivers 16
3.1.1 Increased Emphasis on Cost-Effective Healthcare 16
3.1.2 Availability of New Technologies 16
3.1.3 FDA Regulations 17
3.1.4 Economic Benefits in Drug Development 18
3.1.5 Rising Prevalence of Cancer 18
3.1.6 Demand for Targeted Therapies 18
3.2 Market Barriers 19
3.2.1 Reimbursement Landscape 19
3.2.2 Limited Clinical Use 19
3.2.3 Competitors Using the Same Biomarkers 20
3.2.4 Competition with Laboratory-Developed Tests 21
3.2.5 Emergence of Next Generation Sequencing 21
3.2.6 Linking Tests to Specific Instruments Limits Laboratories 22
3.2.7 Physician Resistance 23
3.3 Unmet Needs 24
3.3.1 Improving Selection for Existing Cancer Treatments 24
3.3.2 Need for Objective Tests 25
3.3.3 Need for High-Throughput Tests 26
3.3.4 Certainty of Reimbursement 28
3.3.5 Quantity of Tissue Required 29
3.3.6 Clarification on When to Test Patients 31
3.3.7 Accuracy of Techniques 35
3.3.8 Test Complexity Leading to Increased Process Failure 38
4 Market Access 39
4.1 Overview 39
4.2 Regulatory Issues and Recalls 39
4.2.1 FDA Regulation 39
4.2.2 Recalls 40
4.3 Reimbursement Trends 41
4.3.1 US 41
4.3.2 France 41
4.3.3 Germany 42
4.3.4 Italy 42
4.3.5 Spain 43
4.3.6 UK 44
4.3.7 China 45
4.3.8 India 45
4.3.9 Japan 46
4.3.10 Brazil 46
4.4 Mergers, Acquisitions, and Key Partnerships 48
5 Product Assessment 52
5.1 Technology Overview 52
5.1.1 Immunohistochemistry 52
5.1.2 In Situ Hybridization 53
5.1.3 Polymerase Chain Reaction 54
5.1.4 Next Generation Sequencing 55
5.2 Marketed Products 56
5.2.1 Breast Cancer Companion Diagnostic Tests 56
5.2.2 Colorectal Cancer Companion Diagnostic Tests 57
5.2.3 Melanoma Companion Diagnostic Tests 58
5.2.4 Non-Small Cell Lung Cancer Companion Diagnostic Tests 58
5.3 Pipeline Products 59
5.4 Clinical Trials 61
6 Competitive Assessment 62
6.1 Company Share Analysis 62
6.1.1 Global Analysis 62
6.1.2 US Company Share Analysis 62
6.2 Trends in Corporate Strategy 63
6.3 Company Profiles 64
6.3.1 Abbott Laboratories 64
6.3.2 Agilent Technologies (Dako) 66
6.3.3 bioMérieux 69
6.3.4 Illumina 71
6.3.5 Leica Microsystems 72
6.3.6 Life Technologies (Thermo Fisher Scientific) 74
6.3.7 Qiagen 76
6.3.8 Roche 78
7 Testing Trends 82
7.1 Breast Cancer Companion Diagnostic Tests 82
7.2 Colorectal Cancer Companion Diagnostic Tests 84
7.3 Melanoma Companion Diagnostic Tests 85
7.4 Non-Small Cell Lung Cancer Companion Diagnostic Tests 87
8 Market Outlook 89
8.1 Global Overview 89
8.2 US 91
8.3 France 93
8.4 Germany 95
8.5 Italy 97
8.6 Spain 99
8.7 UK 101
8.8 Japan 103
8.9 China 105
8.10 India 108
8.11 Brazil 110
9 Appendix 113
9.1 Bibliography 113
9.2 Abbreviations 117
9.3 Report Methodology 121
9.3.1 Overview 121
9.3.2 Coverage 121
9.3.3 Secondary Research 121
9.3.4 Forecasting Methodology 122
9.3.5 Primary Research – Key Opinion Leader Interviews 123
9.4 About the Authors 124
9.4.1 Analysts 124
9.4.2 Tyler Fletcher, Global Head of Medical Devices 125
9.5 About MediPoint 126
9.6 About GlobalData 126
9.7 Disclaimer 127

1.1 List of Tables
Table 1: Possible Companion Diagnostic Test Platform Technologies 14
Table 2: Regulatory Issues and Recalls, 2014-2016 40
Table 3: Mergers and Acquisitions, 2016 48
Table 4: Key Partnerships in 2016 49
Table 5: Breast Cancer Companion Diagnostic Tests, 2016 56
Table 6: CRC Companion Diagnostic Tests, 2016 57
Table 7: Melanoma Companion Diagnostic Tests, 2016 58
Table 8: NSCLC Companion Diagnostic Tests, 2016 59
Table 9: Companion Diagnostic Tests Pipeline, 2014 60
Table 10: Key Clinical Trials Utilizing Companion Diagnostic Tests Linked to Specific Drug Therapies 61
Table 11: Company Profile - Abbott Laboratories 65
Table 12: Abbott Laboratories Portfolio Assessment, 2016 66
Table 13: SWOT Analysis - Abbott Laboratories 66
Table 14: Company Profile - Agilent Technologies 67
Table 15: Agilent Technologies Portfolio Assessment, 2016 68
Table 16: SWOT Analysis - Agilent Technologies 69
Table 17: Company Profile - bioMérieux 70
Table 18: bioMérieux Portfolio Assessment, 2016 70
Table 19: SWOT Analysis - bioMérieux 71
Table 20: Company Profile - Illumina 71
Table 21: SWOT Analysis - Illumina 72
Table 22: Company Profile - Leica 73
Table 23: Leica Portfolio Assessment, 2016 73
Table 24: SWOT Analysis - Leica 74
Table 25: Company Profile - Life Technologies (Thermo Fisher Scientific) 75
Table 26: Life Technologies Portfolio Assessment, 2016 75
Table 27: SWOT Analysis - Life Technologies 76
Table 28: Company Profile - Qiagen 77
Table 29: Qiagen Portfolio Assessment, 2016 77
Table 30: SWOT Analysis - Qiagen 78
Table 31: Company Profile - Roche 79
Table 32: Roche Portfolio Assessment, 2016 80
Table 33: SWOT Analysis - Roche 81
Table 34: Breast Cancer Companion Diagnostic Testing Volume (thousands), 2014-2023 82
Table 35: CRC Companion Diagnostic Testing Volume (thousands), 2014-2023 84
Table 36: Melanoma Companion Diagnostic Testing Volume (thousands), 2014-2023 86
Table 37: NSCLC Companion Diagnostic Testing Volume (thousands), 2014-2023 88
Table 38: Global Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 90
Table 39: US Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 91
Table 40: France Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 94
Table 41: Germany Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 96
Table 42: Italy Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 98
Table 43: Spain Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 100
Table 44: UK Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 102
Table 45: Japan Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 104
Table 46: China Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 106
Table 47: India Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 108
Table 48: Brazil Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 111

1.2 List of Figures
Figure 1: Reasons for Companion Diagnostic Test Failure in the SATURN trial 29
Figure 2: Female Breast Cancer Treatment Patterns by Stage, 2008 32
Figure 3: Colon Cancer Treatment Patterns by Stage, 2008 33
Figure 4: Lung Cancer Treatment Patterns by Stage, 2008 34
Figure 5: Global Company Share Analysis, 2016 62
Figure 6: US Company Share Analysis, 2016 63
Figure 7: Breast Cancer Companion Diagnostic Testing Volume, 2014-2023 83
Figure 8: CRC Companion Diagnostic Testing Volume, 2014-2023 85
Figure 9: Melanoma Companion Diagnostic Testing Volume, 2014-2023 86
Figure 10: NSCLC Companion Diagnostic Testing Volume, 2014-2023 88
Figure 11: Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 90
Figure 12: US Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 92
Figure 13: France Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 94
Figure 14: Germany Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 96
Figure 15: Italy Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 98
Figure 16: Spain Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 100
Figure 17: UK Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 102
Figure 18: Japan Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 104
Figure 19: China Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 106
Figure 20: India Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 109
Figure 21: Brazil Cancer Companion Diagnostic Test Market Value ($m), 2014-2023 111

【掲載企業】

Abbott Laboratories
Agilent Technologies (Dako)
bioMérieux
Illumina
Leica Microsystems
Life Technologies (Thermo Fisher Scientific)
Qiagen
Roche

【レポートのキーワード】

腫瘍学向けコンパニオン診断

★調査レポート[腫瘍学向けコンパニオン診断の世界市場分析・予測] (コード：GDME0245MAR)販売に関する免責事項を必ずご確認ください。
★調査レポート[腫瘍学向けコンパニオン診断の世界市場分析・予測]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のコンパニオン診断癌バイオマーカー市場2016
    QYR61216944 / QYResearch / 2016年10月27日 / ※当調査レポートでは、世界のコンパニオン診断癌バイオマーカー市場について調査・分析し、市場概観、市場動向、コンパニオン診断癌バイオマーカーの世界市場規模、市場予測、地域別市場規模（日本市場、中国市場、米国市場、欧州市場など）、用途別市場分析、製造コスト分析、主要なメーカー分析（企業概要、主な製品概要、生産・販売動向、連絡先など）、種類別価格分析、価格情報、市場環境分析、輸出・輸入データ、市場シェア分析などを含め、以下の構成でお届けいたします。 ・コンパニオン診断癌バイオマーカーの世界市場：市場概要 ・コンパニオン診断癌バイオマーカーの世界市場：市場動向 ・コンパニオン診断癌バイオマーカーの世界市場：市場規模、市場規模予測 ・コンパニオン診断癌バイオマーカーの地域別市場規模（日本市場、中国市場、アメリカ市場、ヨーロッパ市場など） ・コンパニオン診断癌バイオマーカーの世界市場：用途別市場分析 ・コンパニオン診断癌バイオマーカーの製造コスト分析 ・コンパニオン診断癌バイオマーカーの企業間競争状況 ・コンパニオン診断癌バイオマーカーの主要なメーカー分析（企業情報、主な製品概要、生産・販売動向、連絡先など） ・コンパニオン診断癌バイオマーカーの種類別価格分析...Notes:Production, means the output of Companion Diagnostic Cancer Biomarkers Revenue, means the sales value of Companion Diagnostic Cancer Biomarkers This report studies Companion Diagnostic Cancer Biomarkers in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering Abbott Diagnostics Agilent Technologies Eli Lilly & Co. EUSA Pharma CytoCore, Inc. GE Healthcare Bruker Daltonics, Inc. Biomarker Technologies, LLC BioCurex, Inc. Asuragen, Inc. DiagnoCure, Inc. Beckman Coulter, Inc. Market Segment by Regions, this report splits Global into several key Regions, with...
  • 次世代がん診断の世界市場予測
    VGAIN705041 / visiongain / 2017年5月 / 当調査レポートでは、次世代がん診断の世界市場について調査・分析し、次世代がん診断の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 ・レポートの概要 ・イントロダクション ・次世代がん診断の世界市場 　（市場規模予測、市場動向、市場の成長要因・阻害要因など） ・次世代がん診断の世界市場：セグメント別市場分析 ・次世代がん診断の世界市場：地域別市場分析、市場規模予測 ・市場環境分析 ・専門家の見解 ・主要企業分析...The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021. While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu. Companion cancer diagnostics can be costly but we...
  • ファーマコゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の世界市場分析
    GVIEW70714019 / Grand View Research / 2017年6月9日 / 本調査レポートでは、ファーマコゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の世界市場について調査・分析し、ファーマコゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の世界市場動向、ファーマコゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）の世界市場規模、市場予測、セグメント別ファーマコゲノミクス技術/セラノスティクス/コンパニオン診断（CDx）市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。...The global pharmacogenomics technology (theranostics and companion diagnostics) market is expected to reach USD 18.3 billion by 2025, according to a new report by Grand View Research, Inc. Diagnostics is coming to grips with the wave of pharmacogenomic tests that are followed by new biological therapy introductions. These tests enable cost-effective treatment and also add value to the process of drug-development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to significant source of progress in this market. In addition, pharmacogenomics testing products aid...
  • 癌診断の世界市場見通し2017-2023
    SMRC71002025 / Stratistics MRC / 2017年9月 / 当調査レポートでは、癌診断の世界市場について調査・分析し、癌診断の世界市場規模、市場動向、関連企業分析などを含め、以下の構成でお届けいたします。 - エグゼクティブサマリー - 序文 - 癌診断の世界市場：市場動向分析 - 癌診断の世界市場：競争要因分析 -...According to Stratistics MRC, the Global Cancer Diagnostics market is expected to grow from $8.54 billion in 2016 to reach $22.41 billion by 2023 with a CAGR of 14.8 %. Increasing incidence of cancer diseases, growing awareness about health care, and recent technological advancements in diagnostic devices are some of the factors propelling the market growth. In addition, favorable government reimbursement policies, increasing investments in research and development activities are some other factors boosting the market growth during the forecast period. On the other hand, high costs of diagnostic devices, strict regulations for new product approvals are the factors limiting...
  • がん用バイオマーカーの世界市場予測（～2022年）：タンパク質バイオマーカー、遺伝子バイオマーカー
    MAM-MD-5627 / MarketsandMarkets / 2017年10月5日 / MarketsandMarketsが発行した当調査レポートでは、がん用バイオマーカーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別分析、がんタイプ別分析、技術別分析、用途別分析、がん用バイオマーカーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022. Over the years, the cancer biomarkers market has evolved significantly owing to the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, an unfavorable regulatory and reimbursement scenario and the high capital investments required for biomarker development and validation are some factors expected to restrain the market. The cancer biomarkers...
  • トロポニン診断検査：医療機器パイプライン分析2017
    GDME0428EPD / GlobalData / 2017年9月1日 / ...Troponin Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, “Troponin Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Troponin Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Troponin Diagnostic Tests pipeline products. This...
  • コンパニオン診断（CDx）の世界市場予測（～2022年）
    MAM-MD5463 / MarketsandMarkets / 2017年8月1日 / 当調査レポートでは、コンパニオン診断（CDx）の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、技術別分析、疾患別分析、需要先別分析、地域別分析、コンパニオン診断（CDx）の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global market is projected to reach USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 20.1%. The growth of this market is majorly driven by the factors such as improvements in regulatory guidelines, growing need for targeted therapies, rising cancer incidence across the globe, and increasing collaborations and partnerships for companion diagnostics test development. The report analyzes the companion diagnostics market by product & service, technology, indication, end user, and region. On the basis of product & service, the assay kits & reagents segment accounted for the largest share in 2016, owing to...
  • 肝臓がん診断検査：医療機器パイプライン分析2017
    GDME0400EPD / GlobalData / 2017年8月1日 / ...Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 Summary GlobalData's Medical Devices sector report, “Liver Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Liver Cancer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Cancer Diagnostic...

    • ◆H&Iグローバルリサーチのお客様（例）◆